Search clinical trials for: A PD-1 inhibitor

Total 7184 results

Navy General Hospital, Beijing

Recruiting

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Refractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin Lymphoma

China
CureVac
Syneos Health; Cromos Pharma LLC

Active, not recruiting

Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

Carcinoma, Adenoid Cystic | Melanoma (Skin) | Squamous Cell Carcinoma of the Skin | Carcinoma, Squamous Cell of Head and Neck

Spain, France, Austria, Germany, Russian Federation
Shanghai Zhongshan Hospital

Not yet recruiting

PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7

Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and...

Recruiting

PD1 and PARP for Maintenance Therapy in NSLLC

Lung Cancer

China
University Hospital, Montpellier

Completed

Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation (ImmunEO)

Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies

France
Sun Yat-sen University

Recruiting

Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial (AIPD-1)

Hepatocellular Carcinoma

China
Ruijin Hospital

Recruiting

A Combination Study of CAR-T Therapy in r/r B-NHL

Diffuse Large B Cell Lymphoma

China
Fudan University
Shanxi Province Cancer Hospital; Inner Mongolia Cancer Hospital Affiliated...

Recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Advanced Thyroid Cancer Patients Who Received Target Therapy

China
Xiaorong Dong

Unknown

Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

NSCLC | Anlotinib | PD-1/L1 Inhibitor
Fudan University

Active, not recruiting

Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer

Thyroid Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer (AIPAAIAEC)

Esophageal Neoplasms

China
The First Hospital of Jilin University

Not yet recruiting

CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy

Gastric Cancer | Magnetic Resonance Imaging | Neoadjuvant Chemotherapy | Neoadjuvant Immunotherapy | Tomography, X-Ray Computed
Ruijin Hospital

Not yet recruiting

PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT

Lymphoma, Large B-Cell, Diffuse | Chemotherapy | Transplantation

China
Fujian Cancer Hospital

Not yet recruiting

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NSCLC Stage IV

China
Dalian University

Unknown

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Non-small Cell Lung Cancer
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Refractory Melanoma | HLA-A2 Positive Cells Present

United States
The First Affiliated Hospital of Guangdong Pharmaceutical...
Guangzhou Anjie Biomedical Technology Co., Ltd.

Unknown

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Advanced Esophageal Cancer

China
Pfizer

Active, not recruiting

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Renal Cell Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bile Duct Cancer | Endometrial Cancer | Urothelial Cancer | Lung Squamous Cell Carcinoma | Melanoma Cancer

United States, Taiwan, Korea, Republic of, Australia, Slovakia
Ruijin Hospital

Recruiting

PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT

Lymphoma, Large B-Cell, Diffuse | Chemotherapy | Transplantation

China
Shanghai Changzheng Hospital

Unknown

Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer

Colorectal Cancer | Immunotherapy

China
Shanghai Zhongshan Hospital

Unknown

Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant

Liver Transplantation | Hepatocellular Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection

Hepatocellular Carcinoma | Graft Rejection | Immunotherapy | Immune Checkpoint Inhibitor

China
Chen Xiaoping

Recruiting

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

HCC

China
Mahmoud Ramadan mohamed Elkazzaz

Not yet recruiting

CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients

COVID-19 Respiratory Infection
Waterstone Hanxbio Pty Ltd

Completed

The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies

Advanced Solid Tumor

Australia
LI XIN-XIANG

Not yet recruiting

A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis (Miracle-2)

Advanced Rectal Cancer | Distal Metastasis

China
Sun Yat-sen University

Recruiting

Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer

Gastric or Gastroesophageal Junction Adenocarcinoma

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Soft Tissue Sarcoma | Uterine Cancer | Advanced Non Small Cell Lung Cancer

China
Cancer Hospital of Guangxi Medical University

Recruiting

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Sintilimab

China
Hutchison Medipharma Limited

Recruiting

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Extensive-Stage Small Cell Lung Cancer

China
Northwestern University
National Cancer Institute (NCI)

Recruiting

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

Locally Advanced Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Oncocytic Carcinoma

United States
Janssen Research & Development, LLC

Recruiting

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (TRIMM-3)

Relapsed/ Refractory Multiple Myeloma

United States, Germany, Spain, France
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma

Chondrosarcoma

China
Shanghai Pulmonary Hospital, Shanghai, China

Active, not recruiting

CX3CR1+T Cell Predict Immunotherapy Efficacy

Non-small Cell Lung Cancer

China
Sun Yat-sen University

Recruiting

PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial (PLATIC)

Hepatocellular Carcinoma

China
Beijing YouAn Hospital
Beijing Gene Key Life Technology Co., Ltd.

Recruiting

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Hepatocellular Carcinoma

China
Agenus Inc.

Completed

Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Cervical Cancer | Advanced Cancer

France, United States, Belgium, Australia, Spain, Estonia, Brazil, Chile, Poland
Peking University First Hospital
YiZhou International Cancer Hospital

Unknown

Combination of Hypofractionated Proton Therapy With Immunotherapy (I-HypoPT)

Immunotherapy | Proton Therapy
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma (IMplus)

Head and Neck Squamous Cell Carcinoma

China
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients

Anal Canal Cancer | Anal Squamous Cell Carcinoma | Anal Cancer | Anal Canal Cancer Stage III

China
BioAtla, Inc.

Recruiting

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Recurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell Carcinoma of the Head and Neck

United States
Cancer Institute and Hospital, Chinese Academy...

Active, not recruiting

Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma

Radiotherapy | Sintilimab | Concurrent Chemoradiotherapy | Immunonutrition | Locally Advanced Esophageal Squamous Cell Carcinoma

China
Fudan University

Not yet recruiting

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

NSCLC Stage IV

China
Jounce Therapeutics, Inc.

Completed

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies

Cancer

United States
First Affiliated Hospital of Zhejiang University

Unknown

Treatment of PD-1 Inhibitor in AIDS-associated PML (TPAP)

Progressive Multifocal Leukoencephalopathy | AIDS

China
Tianjin Medical University Cancer Institute and...

Recruiting

Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

Hepatocellular Carcinoma | Hepatocellular Carcinoma Non-resectable

China
Wu Jun

Recruiting

Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study

Gastric Cancer

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Cholangiocarcinoma

China
Beijing Tongren Hospital

Not yet recruiting

Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma, Nasal Type

Search clinical trials for: A PD-1 inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations